{"entity":{"id":"black-diamond-therapeutics","kind":"company","name":"Black Diamond Therapeutics","aka":[],"tldr":"Black Diamond Therapeutics designs cancer pills that hit whole families of mutations in a growth protein at once. Its lead drug, silevertinib, targets mutated EGFR in lung cancer and brain tumours.","summary":"Black Diamond Therapeutics is a Cambridge, Massachusetts precision oncology company whose MAP platform designs small molecules that inhibit families of oncogenic mutations. Its lead candidate, silevertinib (formerly BDTX-1535), is a brain-penetrant, mutant-selective EGFR inhibitor: the company lists phase 2 studies in first-line and second/third-line EGFR-mutant non-small cell lung cancer (with FDA Fast Track designation for C797S-positive patients and final phase 2 data at ASCO 2026) and a randomised phase 2 trial in newly diagnosed glioblastoma initiated in the second quarter of 2026. BDTX-4933, a RAF inhibitor for RAF/RAS-mutant solid tumours, has been licensed to Servier, and BDTX-4876 (FGFR2/3) is preclinical. The company completed its Nasdaq IPO in February 2020, raising 231.3 million US dollars gross.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://blackdiamondtherapeutics.com/"},{"label":"Pipeline","url":"https://blackdiamondtherapeutics.com/pipeline-programs/pipeline"},{"label":"Q4 2019 results noting IPO proceeds (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154120000008/bdtx-exhibit991.htm"}],"tags":[],"related":[],"cancers":["nsclc","glioblastoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["egfr","braf","fgfr2"],"drugs":["silevertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05256290","nct07326566"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced. The 'braf' target tag reflects the RAF programme BDTX-4933 (RAF/RAS-mutant tumours) rather than a BRAF-specific claim."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://blackdiamondtherapeutics.com/","ticker":"BDTX","stage":"public","investors":[],"funding":[{"round":"IPO","year":2020,"amountUsd":231300000,"source":"https://www.sec.gov/Archives/edgar/data/1701541/000170154120000008/bdtx-exhibit991.htm","note":"12,174,263 shares including full over-allotment; gross proceeds 231.3 million US dollars, completed February 2020"}]},"route":"/companies/black-diamond-therapeutics/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"}],"drug":[{"id":"silevertinib","kind":"drug","name":"Silevertinib","route":"/drugs/silevertinib/"}],"trial":[{"id":"nct05256290","kind":"trial","name":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","route":"/trials/nct05256290/"},{"id":"nct07326566","kind":"trial","name":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","route":"/trials/nct07326566/"}],"company":[{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/"}],"roadmap":[{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/"}]}}